Metabolic disorders are a major concern during antiretroviral therapy, especially for their potential to increase cardiovascular disease risk. In a multicenter, prospective study conducted in patients exposed to an antiretroviral regimen including lopinavir boosted with ritonavir, an early and sustained increase of high-density lipoprotein cholesterol was observed over a 72-week period. This increase was positively correlated with the exposure to lopinavir/ritonavir during the first 24 weeks.
to lipid-lowering drug therapy and/or with a hypertriglyceridemia (8.6 mmol/L) 3 months prior were not eligible. An initial, 24-week study period was anticipated with an additional 72-week visit. Plasma lipids were assessed after a 12-hour fasting period at weeks 2, 12, 24, and 72. Total cholesterol (TC) and triglyceride (TG) concentrations were measured by enzymatic colorimetry (Roche Diagnostics). Lowdensity lipoprotein cholesterol (LDL-C) and HDL-C were determined by a direct method (Hydrasys SEBIA). All plasma lopinavir (LPV) and ritonavir (RTV) assays were done in a central pharmacology laboratory, using a high-performance liquid chromatography method with a detection limit of 50 ng/mL. The trough (C min ) plasma levels were recorded 10 to 14 hours after the last drug intake. The comparison of continuous variables during follow-up was performed using the Wilcoxon paired test, and the correlation between lipid parameters and LPV concentrations was analyzed by the Spearman correlation test. A multiple linear regression model was used for adjustment on age and baseline lipid levels.
A total of 58 patients (Table 1) were included and completed the initial 24-week follow-up. Of the 35 ARV drug-experienced patients, 14 had received a PI (nelfinavir, 6; indinavir, 6; saquinavir, 1; and amprenavir, 1) and 15 had received a nonnucleoside reverse transcriptase inhibitor (NNRTI), namely efavirenz (8) and nevirapine (NVP) (7) . Six patients had received a combination of 3 nucleoside reverse transcriptase inhibitors (NRTIs), namely zidovudine (ZDV), lamivudine (3TC), and abacavir. Before inclusion, NRTI associated with PI or NNRTI in experienced patients were the following: 3TC (21), ZDV (15) , stavudine (d4T) (9), didanosine (10), ABC (10) , and tenofovir (5). At inclusion, 31 patients were prescribed a backbone regimen containing ZDV, whereas 27 received nonthymidine analogues. Pretreated patients differed from the ARV-naive patients by a longer duration of HIV infection (10.4 vs 1.4 years, P < .001), a higher CD4 count (206 vs 117 cells/mm 3 , P < .02), a lower HIV-RNA load (4.01 vs 5.1 log copies/mL, P < .001), and a higher HDL-C level (0.94 vs 0.65 mmol/L, P < .004). The additional 72-week visit was completed by 30 patients, in whom clinical and biological characteristics were similar to that of the overall study population (Table 1) . Among the 28 patients not completing this visit, 12 were lost to follow-up, 10 discontinued LPV/r (5 for inclusion in a phase 3 protocol, 3 for a switch to a once-daily regimen, and 2 for personal convenience), and 6 were noncompliant (no detectable LPV plasma concentration at week 72). The nucleoside backbone remained Baseline prevalence of hypertriglyceridemia (TG >5.6 mmol/L), high-plasma LDL-C (>4.9 mmol/L), and low-plasma HDL-C (<1 mmol/L) were 1.7% 8 .6% (n ¼ 5), and 82.7% (n ¼ 48), respectively. The evolution of lipid profiles is reported for both the baseline study population until week 24 (Table 2 ) and the subgroup of patients reaching 72-week visit (Figure 1 ). An early significant increase in plasma TG occurred at week 2. Total cholesterol and LDL-C peaked at week 12, with an overall increase in plasma lipid concentration. These fractions remained elevated with no further increase between week 12 and week 24. A strong increase (þ28%) in HDL-C was observed at week 24, with more than half of the patients reaching plasma HDL-C >1 mmol/L. In the subgroup of patients completing the additional 72-week followup, plasma HDL-C appeared to increase steadily (mean HDL-C ¼ 1.50 mmol/L compared to 0.77 mmol/L at baseline, P < .001) and all patients had a HDL-C >1 mmol/L at week 72. Notably, LDL-C significantly decreased between week 24 and week 72 (3.95 mmol/L vs 3.15 mmol/L, respectively, P ¼ .0001), whereas TG levels significantly increased but remained moderately elevated ( Throughout the initial 24-week treatment period, nonsignificant variations in LPV C min plasma levels were observed (5400 mg/L at week 12 and 5264 mg/L at week 24). Moreover, these levels remained stable in the subgroup of patients evaluated at week 72 (4828 mg/L). Plasma lipids appeared independent from plasma LPV C min at all time points. However, analysis using multiple linear regression showed a positive correlation between the increase in HDL-C and the area under the LPV C min time curve in-between week 2 and week 24 (P < .008). This relationship was independent of age, ethnic origin, the estimated duration of HIV infection, prior treatment status, and immunologic-virologic outcome.
The study presented herein revealed a positive and sustained effect of constant exposure to LPV/r on HDL-C with no deleterious long-term increase of LDL and TG in ARV-naive and pretreated patients. These results differ from previous studies investigating the efficacy of LPV/r 6 in which a less favorable lipid profile had been reported. Nevertheless, measurements of TC and TG were not performed after a 12-h fasting period in these studies, and no data on the main fraction of cholesterol associated with cardiovascular risk were available. Previous studies reported divergent results regarding HDL-C variations in HIV-infected patients, showing no change, 7 a decrease, 8 or an increase 9 in plasma HDL-C under LPV/r or other PI-containing ARV regimens. The present study included only patients without lipid-lowering drugs, so that the observed effect of LPV/r on lipid subfractions would not be affected by such treatment. In these patients, fasting plasma HDL-C increased significantly to such an extent rarely obtained with lipid-lowering drugs in dyslipidemic HIV-infected patients. 10 The physiopathologic mechanisms underlying this finding may be due to various causes. A direct effect of the drug on lipoproteins must be considered, especially after finding a positive correlation between the LPV plasma concentrations and the level of HDL-C. This effect is supported by the results of a 2-week metabolic study in healthy volunteers, showing that LPV received at a dose of 400 mg BID increased HDL-C by 6.7%. 11 However, an increase in HDL-C rate has also been observed in ARV-naive patients treated with other PIs such as darunavir or fosamprenavir, 5, 12 suggesting that a controlled HIV replication largely contributes to improving HDL status. This is also illustrated by the fact that the LPV area under the curve reflecting the continuous exposure to the drug (associated with the controlled HIV infection) is significantly correlated with the increase of HDL concentration. Furthermore, the importance of controlled HIV replication was suggested by the results of the SMART study, where a higher risk of cardiovascular events was observed when treatment was interrupted. 13 Some limitations arise from this study. First, previous dislipidemic patients have been excluded from the study and by doing so, we might have biased the results concerning lipids evolution. However, it is already well known that patients with previous lipid abnormalities might develop hypertriglyceridemia and total hypercholesterolemia while on LPV/r. 14 Such a treatment is therefore not recommended in those patients. Second, the number of patients included in the study was small, especially when considering those completing the 72-week followup. However, the lipid profiles of all those patients were very well characterized and the causes of stepping out of the study were not related to the outcome, and thus, did not induce any bias regarding lipids evaluation. Third, the drugs added to LPV/r could have influenced the lipid profile in themselves, as described with thymidine analogues such as ZDV or d4T, 15 or previous treatment with PIs. However, no patient was treated with d4T in this study. Furthermore, the lipid profile of patients treated with ZDV was not different than that of patients treated with other nucleosides at any point during follow-up. Prior treatment with PIs also did not influence the outcome.
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Further studies may determine if the effect of LPV, and more generally PI-containing regimens, on lipid profiles can be translated into a long-term, cardiovascular benefit in HIV-infected patients.
